From Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School; Department of Radiation Oncology, and Department of Medical Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute; and Merkel Cell Carcinoma Clinic, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts. From Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School; Department of Radiation Oncology, and Department of Medical Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute; and Merkel Cell Carcinoma Clinic, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
From Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School; Department of Radiation Oncology, and Department of Medical Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute; and Merkel Cell Carcinoma Clinic, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
J Natl Compr Canc Netw. 2016 Oct;14(10):1247-1257. doi: 10.6004/jnccn.2016.0134.
Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy. However, factors associated with disease presentation and outcomes remain uncertain, especially in light of recent changes in workup, such as sentinel lymph node biopsy. Therefore, this study used the SEER database to examine factors that could affect stage at presentation and treatment.
We identified 4,543 patients and evaluated associations between sex, race, age, primary disease site, disease presentation, and treatment. We also used univariate and multivariate analyses to examine the effect of these factors on disease-specific survival (DSS) and overall survival (OS). We specifically conducted subgroup analyses on a more modern cohort of patients with MCC treated between 2006 and 2012.
Male sex, older age, larger tumor size, and primary tumors of the scalp, neck, or trunk were associated with a higher burden of nodal disease. Multivariate predictors of worse DSS/OS in both the recent and overall cohort included age older than 75 years, number of lymph nodes involved, tumors greater than 5 cm, metastatic disease, or lack of radiation therapy. The number of involved nodes was the best predictor of DSS/OS. Associations with radiation therapy were most pronounced in patients with nodal disease and those not undergoing surgery.
Sex, age, tumor size, and primary site of disease correlated with burden of nodal disease in MCC. Associations between disease presentation and treatment strategies such as radiation and DSS and OS have remained relatively constant in the modern era from 2006 to 2012 compared with findings from prior studies.
默克尔细胞癌(MCC)是一种侵袭性皮肤恶性肿瘤。然而,与疾病表现和结局相关的因素仍不确定,尤其是在最近的检查方法(如前哨淋巴结活检)发生变化的情况下。因此,本研究使用 SEER 数据库来研究可能影响疾病表现和治疗的因素。
我们确定了 4543 名患者,并评估了性别、种族、年龄、原发疾病部位、疾病表现和治疗之间的关联。我们还使用单变量和多变量分析来检查这些因素对疾病特异性生存率(DSS)和总生存率(OS)的影响。我们特别对 2006 年至 2012 年间接受治疗的 MCC 患者的更现代队列进行了亚组分析。
男性、年龄较大、肿瘤较大、头皮、颈部或躯干的原发肿瘤与淋巴结疾病负担较高相关。近期和整体队列中 DSS/OS 较差的多变量预测因素包括年龄大于 75 岁、淋巴结受累数目、肿瘤大于 5cm、转移疾病或未接受放疗。淋巴结受累数目是 DSS/OS 的最佳预测因素。与放疗相关的关联在有淋巴结疾病和未行手术的患者中最为明显。
性别、年龄、肿瘤大小和疾病原发部位与 MCC 淋巴结疾病负担相关。与之前的研究相比,在 2006 年至 2012 年的现代时期,疾病表现与治疗策略(如放疗)之间的关联以及 DSS 和 OS 之间的关联相对保持不变。